CA2864118A1 - Formulations of bendamustine - Google Patents
Formulations of bendamustine Download PDFInfo
- Publication number
- CA2864118A1 CA2864118A1 CA2864118A CA2864118A CA2864118A1 CA 2864118 A1 CA2864118 A1 CA 2864118A1 CA 2864118 A CA2864118 A CA 2864118A CA 2864118 A CA2864118 A CA 2864118A CA 2864118 A1 CA2864118 A1 CA 2864118A1
- Authority
- CA
- Canada
- Prior art keywords
- bendamustine
- pharmaceutically acceptable
- polyethylene glycol
- containing compositions
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002707 bendamustine Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 150000002484 inorganic compounds Chemical class 0.000 abstract 1
- 229910010272 inorganic material Inorganic materials 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598729P | 2012-02-14 | 2012-02-14 | |
| US61/598,729 | 2012-02-14 | ||
| PCT/US2013/026187 WO2013123227A1 (en) | 2012-02-14 | 2013-02-14 | Formulations of bendamustine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2864118A1 true CA2864118A1 (en) | 2013-08-22 |
Family
ID=48946112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2864118A Abandoned CA2864118A1 (en) | 2012-02-14 | 2013-02-14 | Formulations of bendamustine |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130210879A1 (enExample) |
| EP (1) | EP2814487A4 (enExample) |
| JP (2) | JP2015506989A (enExample) |
| CN (2) | CN109157535A (enExample) |
| CA (1) | CA2864118A1 (enExample) |
| WO (1) | WO2013123227A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3158991B1 (en) | 2010-01-28 | 2021-03-17 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| ES2718902T3 (es) | 2012-03-20 | 2019-07-05 | Eagle Pharmaceuticals Inc | Composición líquida destinada a ser utilizada en un método de tratamiento de condiciones en respuesta a la bendamustina en pacientes que requieren volúmenes reducidos para administración |
| HUE064884T2 (hu) * | 2012-03-20 | 2024-04-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelések |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| CN109953954A (zh) | 2013-08-27 | 2019-07-02 | V·沃道里斯 | 苯达莫司汀医药组合物 |
| US9603930B2 (en) | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
| JP2016141734A (ja) * | 2015-02-02 | 2016-08-08 | 三菱瓦斯化学株式会社 | ポリアセタール樹脂組成物及び成形体 |
| CN105726472B (zh) * | 2016-03-25 | 2019-12-13 | 南京康玻斯医药科技有限公司 | 苯达莫司汀药剂组合物及应用 |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| WO2018190897A1 (en) * | 2017-04-13 | 2018-10-18 | Onconova Therapeutics, Inc. | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability |
| US11730815B2 (en) | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| JP2020090481A (ja) * | 2018-11-27 | 2020-06-11 | 日本化薬株式会社 | ベンダムスチンを含有する溶液製剤 |
| JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
| CN111166722B (zh) * | 2019-12-07 | 2022-03-25 | 四川汇宇制药股份有限公司 | 一种注射用盐酸苯达莫司汀冻干前药液及其制备方法 |
| CN111557904A (zh) * | 2020-04-09 | 2020-08-21 | 比卡生物科技（广州）有限公司 | 苯达莫司汀组合物及其用途 |
| US11707450B1 (en) | 2022-03-03 | 2023-07-25 | Slayback Pharma Llc | Stable pharmaceutical compositions of bendamustine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223515A (en) * | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2007026771A1 (ja) * | 2005-08-31 | 2007-03-08 | Ono Pharmaceutical Co., Ltd. | 点滴用注射剤 |
| EP2052723A4 (en) * | 2006-08-14 | 2010-07-28 | Eisai R&D Man Co Ltd | STABLE LYOPHILIZED PREPARATION |
| JP5721949B2 (ja) * | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| DE102007003184A1 (de) * | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Verfahren zur Beladung von strukturierten Oberflächen |
| WO2010036702A1 (en) * | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| JP2012525387A (ja) * | 2009-04-28 | 2012-10-22 | セファロン、インク． | ベンダムスチンの経口製剤 |
| EP3158991B1 (en) * | 2010-01-28 | 2021-03-17 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| WO2011151087A1 (en) * | 2010-06-02 | 2011-12-08 | Astellas Deutschland Gmbh | Oral dosage forms of bendamustine |
| US9655898B2 (en) * | 2010-07-28 | 2017-05-23 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
-
2013
- 2013-02-14 WO PCT/US2013/026187 patent/WO2013123227A1/en not_active Ceased
- 2013-02-14 CN CN201811307257.6A patent/CN109157535A/zh active Pending
- 2013-02-14 EP EP13749829.1A patent/EP2814487A4/en not_active Withdrawn
- 2013-02-14 JP JP2014556835A patent/JP2015506989A/ja active Pending
- 2013-02-14 US US13/767,672 patent/US20130210879A1/en not_active Abandoned
- 2013-02-14 CA CA2864118A patent/CA2864118A1/en not_active Abandoned
- 2013-02-14 CN CN201380017489.7A patent/CN104203235B/zh not_active Expired - Fee Related
-
2018
- 2018-01-25 JP JP2018010326A patent/JP2018109005A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109157535A (zh) | 2019-01-08 |
| JP2015506989A (ja) | 2015-03-05 |
| US20130210879A1 (en) | 2013-08-15 |
| CN104203235B (zh) | 2018-11-23 |
| EP2814487A4 (en) | 2015-07-15 |
| EP2814487A1 (en) | 2014-12-24 |
| JP2018109005A (ja) | 2018-07-12 |
| WO2013123227A1 (en) | 2013-08-22 |
| CN104203235A (zh) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2864118A1 (en) | Formulations of bendamustine | |
| EP2528602A4 (en) | FORMULAS FROM BENDAMUSTIN | |
| JP2015506989A5 (enExample) | ||
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| BR112014009146A8 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
| WO2011014850A3 (en) | Topical eutectic-based formulations | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| WO2011012816A3 (fr) | Formulation pharmaceutique | |
| NZ602392A (en) | Stable bortezomib formulations | |
| GT200900192A (es) | Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).- | |
| CA2929865C (en) | Sprayable topical carrier and composition comprising phosphatidylcholine | |
| BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
| WO2013109388A3 (en) | 1,5-naphthyridine derivatives and melk inhibitors containing the same | |
| WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
| WO2018201167A3 (en) | Propionic acid derivatives and methods of use thereof | |
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| WO2013190508A3 (en) | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | |
| AR094407A1 (es) | Protección de ácido 4-amino-3-cloro-6-(4-cloro-2-flúor-3-metoxifenil)piridina-2-carboxílico y los derivados del mismo en los cultivos de cereales | |
| HK1215672A1 (zh) | 用於治療炎症和癌症的吲哚類化合物 | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
| BR112017017643A2 (pt) | formulação farmacêutica tópica | |
| WO2013103924A3 (en) | Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions | |
| EP2722322B8 (en) | 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient | |
| AR080054A1 (es) | Formulaciones antiparasitarias topicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190214 |